Alisertib
Small molecule
Also known as MLN8237
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02038647 NCT02038647 · Small Cell Lung Cancer Registry: NCT02038647 | 2 | Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines (Every cycle for first 6 months and then every 2 months until disease progression or death or up to data cut-off: 03 January 2016 (approximately 22 months)) 2016-01-03 | Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines (Every cycle for first 6 months and then every 2 months until disease progression or death or up to data cut-off: 03 January 2016 (approximately 22 months)): Alisertib + Paclitaxel 101 days (95% CI 80 to 113) | Placebo + Paclitaxel 66 days (95% CI 53 to 83) | not yet graded | link ↗ |
View 1 more trial
NCT06095505 NCT06095505 · Small Cell Lung Cancer Registry: NCT06095505 | 2 | Objective response rate (ORR) within biomarker-defined subgroup (From date of first dose to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 36 months); Duration of response (DOR) within biomarker-defined subgroup (From start date of response (after date of first dose) to first PD, assessed up to 36 months); Disease Control Rate (DCR) within biomarker-defined subgroup (From date of first dose to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 36 months); Progression Free Survival (PFS) within biomarker-defined subgroup (From date of first dose to date of recurrence, progression or death, assessed up to 36 months); Overall Survival (OS) within biomarker-defined subgroup (From date of first dose to death, assessed up to 36 months) 2027-10-30 | In progress: results expected 30 Oct 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (34)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other Aurora kinase A (AURKA) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Small Cell Lung Cancer: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Alisertib: this drug | Phase 2 | Small molecule | Aurora kinase A (AURKA) | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Lurbinectedin | Approved | Small molecule | Alkylating Drug | Partial signal | No reviewed efficacy summary in this indication | |
| Tarlatamab | Approved | Multispecific antibody | DLL3 and CD3 | Partial signal | NCT06211036: Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08). NCT05740566: Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025). | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-706 | Phase 3 | Antibody–drug conjugate | SEZ6 | not yet graded | No reviewed efficacy summary in this indication | |
| Adebrelimab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| AL8326 | Phase 3 | Small molecule | Aurora B / FGFR / VEGFR (multi-kinase) | Weak signal | NCT04890795: ORR 20% (6/30, 4 confirmed responses); median PFS 3.65 months; median OS 10.42 months in 30 evaluable ≥3rd-line SCLC patients (data cutoff Nov 30, 2022) | |
| Atigotatug | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Gocatamig | Phase 3 | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Obrixtamig | Phase 3 | Multispecific antibody | DLL3 (Delta-like ligand 3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Pumitamig | Phase 3 | Multispecific antibody | PD-L1 and VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Risvutatug Rezetecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Serplulimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Tislelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986525 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| DJI136 | Phase 1/2 | Cell therapy | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| Quaratusugene Ozeplasmid (Reqorsa) | Phase 1/2 | Gene therapy / editing | TUSC2 (tumor suppressor gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| VIC-1911 | Phase 1(overall) | Small molecule | Aurora kinase A (AURKA) | Weak signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Alisertib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.